Evaluación del uso del misoprostol en la inducción de parto en gestantes atendidas en el servicio del gineco/obstetricia del Hospital Alfredo Noboa Montenegro, Guaranda enero - julio del 2024.
The main objective of the study was to determine the safety and effectiveness of misoprostol in labor induction, comparing different doses and administration methods. A quantitative and descriptive approach was used to analyze a sample of 59 pregnant women who were between 37 and 40.5 weeks of gesta...
Gorde:
| Egile nagusia: | |
|---|---|
| Beste egile batzuk: | |
| Formatua: | bachelorThesis |
| Argitaratua: |
2024
|
| Gaiak: | |
| Sarrera elektronikoa: | http://dspace.utb.edu.ec/handle/49000/17527 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Etiketa erantsi | Gaia: | The main objective of the study was to determine the safety and effectiveness of misoprostol in labor induction, comparing different doses and administration methods. A quantitative and descriptive approach was used to analyze a sample of 59 pregnant women who were between 37 and 40.5 weeks of gestation. Data were collected from medical records and analyzed statistically. The results indicated that the 25-mcg sublingual dose was the most effective, while 74% of inductions with misoprostol culminated in successful vaginal deliveries, and 26% required cesarean section. 15% of cases presented side effects, with tachysystole being the most common. To reduce risks, the study proposed standardizing the use of misoprostol with specific doses and rigorous monitoring. Misoprostol proved to be a safe and effective medication for inducing labor, with considerable success in vaginal deliveries, confirming its usefulness in obstetric practice. The important keywords were: misoprostol, induction of labor, safety, dosage and adverse effects. The findings suggested that the Alfredo Noboa Montenegro Hospital establish a standard protocol for the use of misoprostol in labor induction. Given its high success rate in inducing vaginal births and its acceptable safety profile, the 25 mcg sublingual dose should be included as an initial standard in this protocol. Finally, it was recommended to conduct more studies to evaluate the application of these recommendations in various contexts and adapt the protocol to the specific needs of the population served. |
|---|